|
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell
- label - Food and Drug Administration
Tarlatamab-dlle is a bispecific DLL3-directed CD3 T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells
- Tarlatamab - Wikipedia
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer [5] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3
- FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY . . . - Amgen
IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
- FDA grants accelerated approval to tarlatamab-dlle for lung cancer
On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc ) for extensive stage small cell lung cancer (ES-SCLC) with disease
- Practical management of adverse events in patients receiving tarlatamab . . .
Tarlatamab received accelerated approval from the US Food and Drug Administration for the treatment of patients with previously treated small cell lung cancer This review summarizes the safety profile of tarlatamab and outlines the strategies used for the management of common adverse events encountered during the DeLLphi‐301 trial INTRODUCTION
- Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages . . .
Tarlatamab, marketed as Imdelltra, is a bispecific T-cell engager (BiTE®) antibody that harnesses the body’s immune system to fight small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine tumors
- DRUG NAME: Tarlatamab - bccancer. bc. ca
Tarlatamab is a bispecific T-cell engager that simultaneously binds to delta-like ligand 3 (DLL3) on tumour cells and CD3 receptors on T cells
|
|
|